History
Creating a bright future through challenges and changes.
Global Expansion ( 2011~ )
- 2023
-
- ISO 9001 certification
- NK Vue® Kit approval in China
- 2022
-
- SuperNK® approved for phase 1/2a clinical trial in Korea [Allogeneic, metastatic gastric cancer]
- SuperNK® approved for phase 1/2a clinical trial in the U.S [Allogeneic, solid cancer]
- Signed MOU for Parkinson’s Foundation in the U.S.
- Acceptance of SuperNK® clinical data poster at American Society of Clinical Oncology(ASCO),
European Society for Medical Oncology(ESMO)
- 2021
-
- SuperNK® approved for phase 1/2a clinical trial in Korea [EGFR-TKI resistant NSCLC]
- SuperNK® phase 1/2a clinical trial completed in Korea
[Stage IV NSCLC; combination of Immune checkpoint Inhibitors]
- The name of the U.S. subsidiary changed to “NKGen Biotech”
- NK Vue® Kit approval in Australia
- Patent registration completed for NK Vue® Kit (1 patent, abroad)
- Acceptance of SuperNK® clinical data poster at Society
for Immunotherapy of Cancer(SITC), Connective Tissue Oncology Society(CTOS)
- 2020
-
- Acceptance of SuperNK® clinical data poster at American Society
of Clinical Oncology(ASCO), American Association for Cancer Research(AACR)
- Signed a joint development agreement with Affimed NV
for targeted NK cell therapy [SNK01-AFM24]
- Protocol amendment approved for SuperNK® Phase
I clinical trial in the U.S.
[Refractory solid tumors; combination of immune
checkpoint inhibitors]
- SuperNK® approved for phase 1/2a clinical trial in the U.S.
[Solid cancer; combined with targeted anticancer drugs]
- SuperNK® approved for phase 1 clinical trial in Mexico
[Alzheimer’s disease]
- NK Vue® Kit approval in Slovakia
- Patent registration completed for SuperNK® (1 patent, abroad)
- Patent registration completed for NK Vue® Kit (17 patents, abroad)
- 2019
-
- Merge of ATGen and NKMAX Co., Ltd.,
Changed the company name to “NKMAX”
- SuperNK® approved for phase 1 clinical trial in the U.S [Refractory Cancer]
- SuperNK® approved for phase 1/2a clinical trial in Korea [Non-small cell lung cancer]
- Patent registration completed for NK Vue® Kit (4 patents, abroad)
- Completion of the U.S. GMP facilities
- 2018
-
- NK Vue® Kit approval in Indonesia, Kazakhstan, and Singapore
- NK Vue® Kit supply agreement signed with major Canadian diagnostics laboratories (Dynacare)
- Patent registration completed for NK Vue® Kit (5 patents, abroad)
- Patent registration completed for SuperNK (2 patents, abroad)
- 2017
-
- NK Vue® Kit supply agreement signed with the U.S., Indonesia, and Kazakhstan
- NK Vue® Kit approval in Thailand / public reimbursement in Türkiye
- Patent registration completed for NK Vue® Kit (2 patents, abroad)
- Set up a corporation office in the U.S. (NKMAX America) and Japan (NKMAX Japan)
- 2016
-
- Patent acquisition for SuperNK® [NK cell culture and treatment technology]
- ATGen H&D, an ATGen subsidiary company, was founded
- NKMAX, an ATGen affiliate company, was founded
- NK Vue® Kit public reimbursement in Korea
- Patent registration completed for NK Vue® Kit (2 patents, abroad)
- Completion of Korea GMP facilities
- 2015
-
- ATGen listed on KOSDAQ with a special case of technology
- 2014
-
- Set up a corporation office in Canada (ATGen Canada)
- Europe CE marking, KGMP and Canada ISO 13485 certification
- New Health Technology Assessment(nHTA) in Korea (NK Vue® Kit)
- NK Vue® Kit approval in Canada
- Patent registration completed for NK Vue® Kit (1 patent, Korea)
- 2013
-
- Selected as promising SME by Gyeonggi Province
- ISO 13485 certification
- Patent registration completed for NK Vue® Kit (1 patent, Korea)
- 2012
-
- Overseas revenue $1M
- PCT Patent registration for NK Vue® Kit (1 patent)
- NK Vue® Kit approval in Korea KMFDS
Growth ( 2006 - 2010 )
- 2009
-
- Developed test kit for influenza enzyme linked immunosorbent assay
- Established Direct online sales system
- 2007
-
- 2006
-
- Designated as a Promising Export Company
- Patent registration completed for SP fusion technology (1 patent, Korea / 1 patent, abroad)
Building Foundation ( Start - 2005 )
- 2005
-
- Patent registration completed for SP fusion technology (3 patents, Korea / 1 patent, abroad)
- 2004
-
- Patent registration completed for SP fusion technology (1 patent, Korea)
- 2003
-
- 2002
-
- Venture Company Certification
- Founded ATGen